COX-2 inhibitors: increased risk of CV events?

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2001年 / 867卷 / 1期
关键词：
Celecoxib; Naproxen; Rofecoxib; Nabumetone; Adverse Event Reporting System;
D O I：
10.2165/00128415-200108670-00001
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2 / 2
相关论文
共 50 条
  • [31] COX-2 inhibitors: cancer prevention or cardiovascular risk?
    Senior, K
    LANCET ONCOLOGY, 2005, 6 (02): : 68 - 68
  • [32] COX-2 inhibitors associated with varying risk of MI
    不详
    FORMULARY, 2005, 40 (01) : 12 - 12
  • [33] Risk of hyperkalemia associated with selective COX-2 inhibitors
    Aljadhey, Hisham
    Tu, Wanzhu
    Hansen, Richard A.
    Blalock, Susan
    Brater, Craig
    Murray, Michael D.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2010, 19 (11) : 1194 - 1198
  • [34] COX-2 inhibitors and cardiovascular risk - Point and counterpoint
    Mandell, BF
    CLEVELAND CLINIC JOURNAL OF MEDICINE, 2001, 68 (11) : 957 - 960
  • [35] Cardiovascular Risk Associated With NSAIDs and COX-2 Inhibitors
    Perry, Laura A.
    Mosier, Charles
    Atkins, Ashton
    Minehart, Megan
    US PHARMACIST, 2014, 39 (03) : 35 - 38
  • [36] Are COX-2 inhibitors a risk factor for cardiovascular disease?
    John, S
    Schmieder, RE
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2002, 127 (04) : 156 - 159
  • [37] COX-2 inhibitors and risk of heart failure - Reply
    Wardle, EN
    LANCET, 2004, 364 (9444): : 1487 - 1487
  • [38] Selective COX-2 inhibitors and risk of myocardial infarction
    Krötz, F
    Schiele, TM
    Klauss, V
    Sohn, HY
    JOURNAL OF VASCULAR RESEARCH, 2005, 42 (04) : 312 - 324
  • [39] Rofecoxib, selective COX-2 inhibitors and cardiovascular risk
    Dhaun, N.
    Maxwell, S. R. J.
    Webb, D. J.
    JOURNAL OF THE ROYAL COLLEGE OF PHYSICIANS OF EDINBURGH, 2005, 35 (02): : 101 - 103
  • [40] Do Some Inhibitors of COX-2 Increase the Risk of Thromboembolic Events?Linking Pharmacology with Pharmacoepidemiology
    David W.J. Clark
    Deborah Layton
    Saad A.W. Shakir
    Drug Safety, 2004, 27 : 427 - 456
12345